Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 11, 2020 at 04:24 pm EST
Share
Sinphar Pharmaceutical Co.,Ltd. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was TWD 639.511 million compared to TWD 577.663 million a year ago. Operating loss was TWD 26.599 million compared to TWD 63.365 million a year ago. Net loss was TWD 9.765 million compared to TWD 10.182 million a year ago. Basic loss per share was TWD 0.06 compared to TWD 0.06 a year ago. For the nine months, sales was TWD 1,847.962 million compared to TWD 1,723.050 million a year ago. Operating loss was TWD 38.954 million compared to TWD 151.511 million a year ago. Net income was TWD 25.547 million compared to net loss of TWD 20.807 million a year ago. Basic earnings per share was TWD 0.15 compared to basic loss per share of TWD 0.12 a year ago.
Sinphar Pharmaceutical Co., Ltd. is principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company is also engaged in the sales of functional food products. The Companyâs principal products include ointment, gel, cream, hard and soft capsules, sugar-coated tablets, film-coated tablets, suppositories, powders and granules, lozenges, soft candies, oral and topical liquid medicines, injections, dry medicated powers, functional food products, medical equipment and cosmetics. The Company mainly sells its products to hospitals, drug stores, clinics, dealers and distributors. Its primary markets are located in Taiwan and overseas countries.
SINPHAR PHARMACEUTICAL CO.,LTD. 
